Management of antiangiogenic therapy-induced hypertension.
about
Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort studyThe Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.Emerging paradigms in cardiomyopathies associated with cancer therapies.Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options.Oncocardiology-Past, Present, and Future: A Review.Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.Drug-Induced Hypertension: Focus on Mechanisms and Management.Confusion of therapeutic approaches.Cardio-oncology: it takes two to translate.Cardio-Oncology: mechanisms of cardiovascular toxicity.Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat.Use of Antihypertensive Drugs in Neoplastic Patients.Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients.Biomimetic delivery of signals for bone tissue engineeringMechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis
P2860
Q30426853-6E3A12F9-086C-4353-A389-9D024949541BQ36106439-2BE94B96-3AC9-4AFD-BD0E-FE0C3F9E3931Q36640122-93368F44-BC2F-4D47-A4D6-1890F9495F4AQ37729290-F41C87A4-BE59-4043-9E5C-3467E6C56395Q38132645-6842990A-8FC6-4BCA-80DA-7AE2385D2810Q38744149-6ADC7CFA-208E-46DE-8AE3-D7974FDC1CFEQ38757141-6A55755A-6E37-49C1-82F1-B2E3908C9324Q38829737-694D909A-CAC1-4D20-AC34-E6EE17B485C1Q38834995-5EFE721B-8722-4E0F-B034-EA52EEF1C5CBQ39186183-A7B770A0-B3C7-4BCC-A7AC-443397C0A7FAQ39268826-0FF2C82F-5090-4F10-BA18-A8EBBD21F823Q42717154-45F78AE3-DB64-48EE-B6B5-6C471785BCDBQ44228500-1239288D-FA1B-48B4-B52A-AB78F3E96897Q48109228-36B7B9E7-2379-4B88-B098-B7693960336FQ48124224-3A31F05A-EA5A-47C8-B663-F0F229B05556Q48342585-3ABBECA4-9CA3-4454-A5C4-85CBE30DF056Q53303141-17F0741F-644C-44B9-9670-BE66E1C5C6E2Q58695509-0B6C12C9-52BC-4091-8C85-E0AEA9087426Q58791422-7CAE93AA-0CE2-4582-9214-39E6415B233C
P2860
Management of antiangiogenic therapy-induced hypertension.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Management of antiangiogenic therapy-induced hypertension.
@ast
Management of antiangiogenic therapy-induced hypertension.
@en
type
label
Management of antiangiogenic therapy-induced hypertension.
@ast
Management of antiangiogenic therapy-induced hypertension.
@en
prefLabel
Management of antiangiogenic therapy-induced hypertension.
@ast
Management of antiangiogenic therapy-induced hypertension.
@en
P2093
P2860
P1433
P1476
Management of antiangiogenic therapy-induced hypertension.
@en
P2093
Benjamin D Humphreys
Emily Robinson
Javid Moslehi
Nilka de Jesus-Gonzalez
P2860
P304
P356
10.1161/HYPERTENSIONAHA.112.196774
P407
P577
2012-07-30T00:00:00Z